AGP Picks
View all

Nepal Healthcare Times
Provided by AGP

Nepal Healthcare Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nepal Healthcare Times.

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on October 8, 2026

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
3 hours ago

Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026

Indeterminate GlobeNewswire
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
3 hours ago

Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors

Indeterminate GlobeNewswire
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
3 hours ago

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

Indeterminate GlobeNewswire
MMI Raises $125M in Series D to Accelerate Commercial Growth of the Symani Surgical System Worldwide
3 hours ago

MMI Raises $125M in Series D to Accelerate Commercial Growth of the Symani Surgical System Worldwide

Indeterminate GlobeNewswire
UCHealth University of Colorado Hospital is using breakthrough technology to expand access to liver transplants
3 hours ago

UCHealth University of Colorado Hospital is using breakthrough technology to expand access to liver transplants

Indeterminate GlobeNewswire
Spirair Announces Publication of Multicenter Study Demonstrating Significant Six-Month Improvements with SeptAlign
3 hours ago

Spirair Announces Publication of Multicenter Study Demonstrating Significant Six-Month Improvements with SeptAlign

Indeterminate GlobeNewswire
ViroMissile Appoints Diane Simeone, M.D., and Matt Mulvey, Ph.D. as Advisors
3 hours ago

ViroMissile Appoints Diane Simeone, M.D., and Matt Mulvey, Ph.D. as Advisors

Indeterminate GlobeNewswire
Bluesight’s 2026 Diversion Trends Report Shows Hospital Diversion Programs Maturing as Technology Use Expands
3 hours ago

Bluesight’s 2026 Diversion Trends Report Shows Hospital Diversion Programs Maturing as Technology Use Expands

Indeterminate GlobeNewswire
Solu Therapeutics Initiates Dosing in Acute Myeloid Leukemia Cohort of the Ongoing Phase 1 Study of STX-0712
3 hours ago

Solu Therapeutics Initiates Dosing in Acute Myeloid Leukemia Cohort of the Ongoing Phase 1 Study of STX-0712

Indeterminate GlobeNewswire
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
4 hours ago

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Indeterminate GlobeNewswire
Cronos Group Inc. to Hold 2026 Third Quarter Earnings Conference Call on November 5, 2026
4 hours ago

Cronos Group Inc. to Hold 2026 Third Quarter Earnings Conference Call on November 5, 2026

Indeterminate GlobeNewswire
Helus Pharma to Host Investor Presentation on October 21, 2026
4 hours ago

Helus Pharma to Host Investor Presentation on October 21, 2026

Indeterminate GlobeNewswire
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
4 hours ago

Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests

Indeterminate GlobeNewswire
Ritedose Opens Advanced Laboratory and Expands Analytical Capabilities to Accelerate Pharmaceutical Innovation—Positioning the Company as a Preferred Partner for Drug Development and Manufacturing
4 hours ago

Ritedose Opens Advanced Laboratory and Expands Analytical Capabilities to Accelerate Pharmaceutical Innovation—Positioning the Company as a Preferred Partner for Drug Development and Manufacturing

Indeterminate GlobeNewswire
What Actually Keeps Weight Off After a Weight Loss Program
4 hours ago

What Actually Keeps Weight Off After a Weight Loss Program

Indeterminate GlobeNewswire
Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET
4 hours ago

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

Indeterminate GlobeNewswire
Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia
4 hours ago

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Indeterminate GlobeNewswire
Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program
4 hours ago

Newron Provides Update on FDA Clinical Hold and Phase 3 ENIGMA-TRS Development Program

Indeterminate GlobeNewswire
BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options
4 hours ago

BioStem Technologies’ CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options

Indeterminate GlobeNewswire
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
4 hours ago

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Nepal Healthcare Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.